-
Something wrong with this record ?
(4-Oxo-2-thioxothiazolidin-3-yl)acetic acids as potent and selective aldose reductase inhibitors
M. Kucerova-Chlupacova, D. Halakova, M. Majekova, J. Treml, M. Stefek, M. Soltesova Prnova,
Language English Country Ireland
Document type Journal Article
- MeSH
- Aldehyde Reductase antagonists & inhibitors metabolism MeSH
- Hep G2 Cells MeSH
- Enzyme Inhibitors chemical synthesis chemistry pharmacology MeSH
- Acetic Acid chemical synthesis chemistry pharmacology MeSH
- Humans MeSH
- Ligands MeSH
- Lens, Crystalline drug effects enzymology MeSH
- Rats, Wistar MeSH
- Rhodanine analogs & derivatives chemistry pharmacology MeSH
- Thiazolidines chemistry pharmacology MeSH
- Binding Sites MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
(4-Oxo-2-thioxothiazolidin-3-yl)acetic acids exhibit a wide range of pharmacological activities. Among them, the only derivative used in clinical practice is the aldose reductase inhibitor epalrestat. Structurally related compounds, [(5Z)-(5-arylalkylidene-4-oxo-2-thioxo-1,3-thiazolidin-3-yl)]acetic acid derivatives were prepared previously as potential antifungal agents. This study was aimed at the determination of aldose reductase inhibitory action of the compounds in comparison with epalrestat and evaluation of structure-activity relationships (SAR). The aldose reductase (ALR2) enzyme was isolated from the rat eye lenses, while aldehyde reductase (ALR1) was obtained from the kidneys. The compounds studied were found to be potent inhibitors of ALR2 with submicromolar IC50 values. (Z)-2-(5-(1-(5-butylpyrazin-2-yl)ethylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid (3) was identified as the most efficacious inhibitor (over five times more potent than epalrestat) with mixed-type inhibition. All the compounds also exhibited low antiproliferative (cytotoxic) activity to the HepG2 cell line. Molecular docking simulations of 3 into the binding site of the aldose reductase enzyme identified His110, Trp111, Tyr48, and Leu300 as the crucial interaction counterparts responsible for the high-affinity binding. The selectivity factor for 3 in relation to the structurally related ALR1 was comparable to that for epalrestat. SAR conclusions suggest possible modifications to improve further inhibition efficacy, selectivity, and biological availability in the group of rhodanine carboxylic acids.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20027591
- 003
- CZ-PrNML
- 005
- 20210114152119.0
- 007
- ta
- 008
- 210105s2020 ie f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.cbi.2020.109286 $2 doi
- 035 __
- $a (PubMed)33038328
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ie
- 100 1_
- $a Kucerova-Chlupacova, Marta $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Heyrovskeho 1203, 500 05, Hradec Kralove, Czech Republic. Electronic address: kucerom@faf.cuni.cz.
- 245 10
- $a (4-Oxo-2-thioxothiazolidin-3-yl)acetic acids as potent and selective aldose reductase inhibitors / $c M. Kucerova-Chlupacova, D. Halakova, M. Majekova, J. Treml, M. Stefek, M. Soltesova Prnova,
- 520 9_
- $a (4-Oxo-2-thioxothiazolidin-3-yl)acetic acids exhibit a wide range of pharmacological activities. Among them, the only derivative used in clinical practice is the aldose reductase inhibitor epalrestat. Structurally related compounds, [(5Z)-(5-arylalkylidene-4-oxo-2-thioxo-1,3-thiazolidin-3-yl)]acetic acid derivatives were prepared previously as potential antifungal agents. This study was aimed at the determination of aldose reductase inhibitory action of the compounds in comparison with epalrestat and evaluation of structure-activity relationships (SAR). The aldose reductase (ALR2) enzyme was isolated from the rat eye lenses, while aldehyde reductase (ALR1) was obtained from the kidneys. The compounds studied were found to be potent inhibitors of ALR2 with submicromolar IC50 values. (Z)-2-(5-(1-(5-butylpyrazin-2-yl)ethylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid (3) was identified as the most efficacious inhibitor (over five times more potent than epalrestat) with mixed-type inhibition. All the compounds also exhibited low antiproliferative (cytotoxic) activity to the HepG2 cell line. Molecular docking simulations of 3 into the binding site of the aldose reductase enzyme identified His110, Trp111, Tyr48, and Leu300 as the crucial interaction counterparts responsible for the high-affinity binding. The selectivity factor for 3 in relation to the structurally related ALR1 was comparable to that for epalrestat. SAR conclusions suggest possible modifications to improve further inhibition efficacy, selectivity, and biological availability in the group of rhodanine carboxylic acids.
- 650 _2
- $a kyselina octová $x chemická syntéza $x chemie $x farmakologie $7 D019342
- 650 _2
- $a aldehydreduktasa $x antagonisté a inhibitory $x metabolismus $7 D000449
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a vazebná místa $7 D001665
- 650 _2
- $a inhibitory enzymů $x chemická syntéza $x chemie $x farmakologie $7 D004791
- 650 _2
- $a buňky Hep G2 $7 D056945
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a oční čočka $x účinky léků $x enzymologie $7 D007908
- 650 _2
- $a ligandy $7 D008024
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a rhodanin $x analogy a deriváty $x chemie $x farmakologie $7 D012236
- 650 _2
- $a thiazolidiny $x chemie $x farmakologie $7 D053778
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Halakova, Dominika $u Centre of Experimental Medicine of Slovak Academy of Sciences, Institute of Experimental Pharmacology and Toxicology, Department of Biochemical Pharmacology, Dubravska Cesta 9, 841 04, Bratislava, Slovak Republic. Electronic address: dominika.halakova@gmail.com.
- 700 1_
- $a Majekova, Magdalena $u Centre of Experimental Medicine of Slovak Academy of Sciences, Institute of Experimental Pharmacology and Toxicology, Department of Biochemical Pharmacology, Dubravska Cesta 9, 841 04, Bratislava, Slovak Republic. Electronic address: magdalena.majekova@savba.sk.
- 700 1_
- $a Treml, Jakub $u Masaryk University, Faculty of Pharmacy, Department of Molecular Pharmacy, Palackeho Tr. 1946/1, 612 00, Brno, Czech Republic. Electronic address: tremlj@pharm.muni.cz.
- 700 1_
- $a Stefek, Milan $u Centre of Experimental Medicine of Slovak Academy of Sciences, Institute of Experimental Pharmacology and Toxicology, Department of Biochemical Pharmacology, Dubravska Cesta 9, 841 04, Bratislava, Slovak Republic. Electronic address: milan.stefek@savba.sk.
- 700 1_
- $a Soltesova Prnova, Marta $u Centre of Experimental Medicine of Slovak Academy of Sciences, Institute of Experimental Pharmacology and Toxicology, Department of Biochemical Pharmacology, Dubravska Cesta 9, 841 04, Bratislava, Slovak Republic. Electronic address: marta.prnova@savba.sk.
- 773 0_
- $w MED00002111 $t Chemico-biological interactions $x 1872-7786 $g Roč. 332, č. - (2020), s. 109286
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33038328 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114152117 $b ABA008
- 999 __
- $a ok $b bmc $g 1607926 $s 1118771
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 332 $c - $d 109286 $e 20201007 $i 1872-7786 $m Chemico-biological interactions $n Chem Biol Interact $x MED00002111
- LZP __
- $a Pubmed-20210105
